



It is a pleasure to congratulate all those who promote the Prix Galien and pharmaceutical research: they play a vital role in the fight against disease throughout the world.

- John Major - 1996




The Prix Galien is a welcome initiative to stimulate creative research and promote excellence.

- Barack Obama, 2008



The Prix Galien honors outstanding achievement in two areas that are critical to human health: science and innovation

- Tedros Adhanom Ghebreyesus - 2018



The Prix Galien Awards are a true celebration of the years of hard work that are required to produce life-changing interventions.

- Bill & Melinda Gates, 2018



ACTORS WIN OSCARS...

INNOVATORS WIN PRIX GALIEN UK

PRIX GALIEN UK

Thursday, 30 May, 2024

Natural History Museum,
London

—  —
PRIX GALIEN
— UNITED KINGDOM —

www.prixgalien.co.uk

NOMINATIONS ARE NOW OPEN

Deadline for submission is March 31

PGUK 2024
QUICK FACT SHEET

CLICK
HERE TO
APPLY

Our annual awards ceremony is a creative recognition of the productive and positive power of partnerships that drive progress in medical science. It is a peer exchange with a public purpose, spanning a diverse range of interests and creating opportunities for networking across professional and scientific groups, academia, governments, patient associations, non-profit organisations, and the media.

AWARDS CEREMONY

When: Thursday, 30 May, 2024
Where: Natural History Museum - London


AWARDS CATEGORIES

- > Best Biotechnology Product
- > Best Digital Health
- > Best Medical Technology
- > Best Pharmaceutical Product
- > Best Public Sector Innovation

HOW TO APPLY

Entries must be submitted online at:
<https://www.galienfoundation.org/PGUK-submissions>

Complete entry guidelines and requirements can be found on our website. Assistance with completing your application is available upon request.



CHARTER FOR THE “BEST PUBLIC SECTOR INNOVATION” CATEGORY Purpose:

The «Best Public Sector Innovation» category recognizes outstanding innovations in healthcare developed within or significantly supported by the public sector. This category aims to spotlight contributions that have profoundly impacted human health, aligning with the Prix Galien’s mission to celebrate excellence and innovation in medical advancements.

Objective:

By introducing this category, the Prix Galien UK Committee aims to underscore the critical role of the public sector in advancing healthcare innovation. It seeks to encourage public institutions, and private life sciences companies to collaborate with the public sector, to pursue groundbreaking work that can lead to significant health benefits globally. However, the innovation must have been majority funded and/or developed by the public sector.

Criteria:

1. **Originality:** The innovation should represent a novel approach or solution in healthcare, showcasing creativity and ingenuity.
2. **Clinical Utility:** The application of innovation in clinical settings or public health must provide clear benefits, improving patient care or health outcomes.
3. **Knowledge Contribution:** The entry should contribute valuable insights or findings that could influence future biomedical research or healthcare practices.
4. **Impact:** The overall effect on improving human health, including accessibility, efficacy, and improvement in quality of life, will be assessed.
5. **Independence from Market Factors:** Consideration of the innovation’s merit will be made without regard to market size, development cost, or distribution challenges.

PLEASE BE AWARE THAT THERE ARE NO APPLICATION FEES

Your submission depends on your physical attendance on May 30th. Entry into this category grants you one complimentary ticket to the ceremony. The cost for an additional individual ticket to the Awards Ceremony is £ 1,450.

ENTRY INCLUDES

- > One complimentary ticket to the Prix Galien UK Ceremony.
- > Product presentation in the 2024 Awards Ceremony Program -- ‘Golden Book’
- > Presentation of award candidates during the Awards Ceremony (30 second video/digital clip)
- > Full page advertisement in the Awards Ceremony Program
- > Industry press publicity for all entries prior to the announcement of the winners
- > Online presentation of each entry on the Prix Galien UK website
- > Video interview with product award category winner at the Prix Galien UK website for one month

PREVIOUS PRIX GALIEN AWARD WINNERS



“What an amazing recognition for our global team, who have spent decades developing and distributing this vaccine. Congratulations.”

Albert Bourla
Chairmand and CEO, Pfizer



“Merck’s mission is to translate science into medically important products that positively impact humanity, so it is natural for us to support the Prix Galien, since it supports exactly that.”

Kenneth C. Frazier
Chairman, Former CEO and President, Merck



“The Galien Foundation brings together the top scientists in the world. You have Nobel Laureates across the spectrum of scientific disciplines meeting and talking with members of the pharmaceutical industry to see what’s going on at the cutting edge, because ultimately that’s going to benefit patients.”

William Hait, MD, PhD
EVP, Chief External Innovation and Medical Officer, and member of the Johnson & Johnson Executive Committee



“Our Prix Galien USA awards [for Cosentyx and Gleevec]... represent years of hard work by our scientists. These wins underscore our commitment to addressing the unmet medical needs of patients through science-based innovation.”

Joseph Jimenez
Former CEO, Novartis



CONTACTS:

Robin Welbers
+1 438 405 9733

robin@galienfoundation.org

Laetitia Parenti
+1 212 685 1592

lparenti@galienfoundation.org



■ **2024** PRIX GALIEN UK COMMITTEE CHAIR

Pr Sir Munir PIRMOHAMED

David Weatherall Chair of Medicine,
University of Liverpool, Liverpool
NHS Chair of Pharmacogenetics

■ **2024** AWARDS COMMITTEE



Pr Jane ADAM

Honorary Professor,
University of Exeter,
Consultant Radiologist,
St George's Hospital London
and former Chair Technology
appraisal committee, NICE



Pr Bruce CAMPBELL

Past Chair NICE
Interventional Procedures
and Medical Technologies
Advisory Committees;
Honorary Vascular
Consultant and Professor,
Exeter



Dr Stephanie KUKU

Chief Knowledge Officer -
Conceivable Life Sciences,
Senior Consultant – Hadrian
Health, Board Member –
Equinox and Board Trustee
– The Kings Fund



Pr Sudhesh KUMAR

Vice President (Health),
University of Warwick and
President of Association of
Innovation, Research and
Technology Organisations,
UK (AIRTO)



Pr Sir Robert LECHLER

Emeritus Senior Vice
President (Health),
King's College London



Pr Andrew MORRIS

Director, Health Data
Research UK &
Professor of Medicine and
Vice Principal Data Science,
University of Edinburgh



Dame June RAINE

Chief Executive,
Medicines UK
Healthcare products
Regulatory Agency



Pr Duncan RICHARDS

Professor of Clinical
Therapeutics,
University of Oxford



Pr Liam SMEETH

Professor of Clinical
Epidemiology and
Director of the London
School of Hygiene
and Tropical Medicine



Pr Rosalind SMYTH

Professor of Child Health, UCL
Great Ormond St. Institute
of Child Health, Vice Dean
Research in the UCL Faculty
of Population Health Sciences
& Vice President (Clinical) UK
Academy of Medical Sciences



Dr Lauren WALKER

Senior Clinical Lecturer in
Clinical Pharmacology &
Therapeutics and Internal
Medicine, University of
Liverpool



Pr Moira WHYTE

Sir John Crofton Professor
of Respiratory Medicine,
University of Edinburgh



AND THE 2024 WINNERS ARE?

—  —
PRIX GALIEN
 — UNITED KINGDOM —

HALL OF FAME

Prix Galien UK juries rigorously select life-changing therapeutics each year. To view the full list of Prix Galien UK winners, beginning in 1990, [click here](#).



The **Prix Galien Award** recognizes outstanding achievements in improving the global human condition through the development of innovative drugs and other treatments.

The Prix Galien was created in 1970 in honor of Galen, the father of medical science and modern pharmacology.

Worldwide, the Prix Galien is regarded as the equivalent of the Nobel Prize in biopharmaceutical research.

	2023	BIMZELX, UCB S.A. / Idefirix, Hansa Biopharma AB Jardiance, Boehringer Ingelheim Inter.	
2023		Guardant360 CDX, Guardant Health Exscientia's end-to-end AI-driven precision medicine platform, Exscientia	2023
2023		ZOLGENSMA, Novartis Pharmaceuticals UK Ltd (Orphan Product) The Randomised Evaluation of COVID-19 Therapy clinical trial, University of Oxford	2023
2022		Rybelsus, NOVO NORDISK LTD. / Red Hot, BEHOLD.AI Cytosponge, CYTED LTD / Spikevax, MODERNA Onpattro, ALNYLAM (Orphan Product)	2022
2018		Galafold, AMICUS THERAPEUTICS Solitaire, MEDTRONIC Spinraza, BIOGEN IONIS	2018
2016		Entresto, NOVARTIS Holoclar, CHIESI (Orphan Product) / Dificlir, ASTELLAS (Real World Evidence)	2016
2014		Bexsero, NOVARTIS / Sirturo, JANSSEN (Orphan Product)	2014
2012		Incivo, JANSSEN / Victrelis, MSD / Mepact, TAKEDA (Orphan Product)	2012
2010		Xarelto, BAYER SCHERING / Firazyr, SHIRE (Orphan Product)	2010
2008		Cervarix, GSK / Gardasil, SPMSD / Exjade, NOVARTIS (Orphan Product)	2008
2006		Xolair, NOVARTIS / Rotarix, GSK / Myozyme, GENZYME (Orphan Product)	2006
2004		Fuzeon, ROCHE / Prevenar, WYETH	2004
2002		Herceptin, ROCHE / Glivec, NOVARTIS	2002
2000		Viagra, PFIZER / Meningitec, WYETH	2000

